Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRV NASDAQ:LTRN NASDAQ:LVTX NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.34$1.32$1.05▼$10.00$42.15M1.66177,972 shs78,189 shsLTRNLantern Pharma$4.03-1.2%$4.08$2.55▼$6.12$44.06M1.47106,382 shs66,098 shsLVTXLAVA Therapeutics$1.56-0.6%$1.45$0.85▼$2.09$41.30M0.5153,275 shs90,924 shsTLPHTalphera$0.54-0.2%$0.46$0.38▼$1.19$11.10M-0.173.37 million shs166,304 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics0.00%+0.75%+6.35%+15.52%-85.88%LTRNLantern Pharma0.00%-10.72%-14.47%+26.71%-0.24%LVTXLAVA Therapeutics0.00%+3.97%+10.56%+18.94%-10.29%TLPHTalphera0.00%-5.85%+34.44%+13.63%-47.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics2.8198 of 5 stars3.53.00.00.02.71.70.6LTRNLantern Pharma2.8898 of 5 stars3.53.00.00.03.80.80.6LVTXLAVA Therapeutics1.8039 of 5 stars3.03.00.00.03.80.00.0TLPHTalphera2.7176 of 5 stars3.85.00.00.02.50.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$17.571,211.30% UpsideLTRNLantern Pharma 3.00Buy$25.00520.35% UpsideLVTXLAVA Therapeutics 2.00Hold$2.6972.12% UpsideTLPHTalphera 3.50Strong Buy$5.00825.93% UpsideCurrent Analyst Ratings BreakdownLatest TLPH, LTRN, ACRV, and LVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025ACRVAcrivon TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.008/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.50(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$4.55 per shareN/ALTRNLantern PharmaN/AN/AN/AN/A$1.16 per shareN/ALVTXLAVA Therapeutics$11.98M3.43N/AN/A$0.76 per share2.05TLPHTalphera$27K410.46N/AN/A$0.32 per share1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$80.56M-$2.25N/AN/AN/AN/A-50.78%-46.08%11/12/2025 (Estimated)LTRNLantern Pharma-$20.78M-$1.78N/AN/AN/AN/A-99.89%-81.58%11/6/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%N/ATLPHTalphera-$13M-$0.40N/AN/AN/AN/A-152.38%-64.32%11/12/2025 (Estimated)Latest TLPH, LTRN, ACRV, and LVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TLPHTalphera-$0.1150-$0.10+$0.0150-$0.10N/AN/A8/13/2025Q2 2025ACRVAcrivon Therapeutics-$0.57-$0.55+$0.02-$0.55N/AN/A8/13/2025Q2 2025LTRNLantern Pharma-$0.53-$0.40+$0.13-$0.40N/AN/A8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/ALTRNLantern PharmaN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A10.3110.31LTRNLantern PharmaN/A3.523.52LVTXLAVA TherapeuticsN/A10.7810.78TLPHTalpheraN/A2.932.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%LTRNLantern Pharma28.62%LVTXLAVA TherapeuticsN/ATLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%LTRNLantern Pharma8.50%LVTXLAVA Therapeutics9.50%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.46 million28.78 millionNot OptionableLTRNLantern Pharma2010.80 million9.88 millionOptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableTLPHTalphera1920.52 million19.87 millionOptionableTLPH, LTRN, ACRV, and LVTX HeadlinesRecent News About These CompaniesTalphera, Inc. Earnings Call Highlights Strategic ProgressAugust 31 at 8:31 PM | tipranks.comTalphera enrolls 17 patients in 70-patient pivotal NEPHRO CRRT clinical trialAugust 27, 2025 | finance.yahoo.comTalphera Announces Achievement of 17 Patient Enrollment Milestone in NEPHRO CRRT Pivotal TrialAugust 25, 2025 | prnewswire.comTalphera, Inc. (NASDAQ:TLPH) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | insidermonkey.comTalphera, Inc.: Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deTalphera Cuts Expenses 14 PercentAugust 15, 2025 | aol.comATalphera Reports Q2 2025 Financial Results and Study ProgressAugust 14, 2025 | tipranks.comTalphera, Inc. (TLPH) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comTalphera lowers 2025 cash operating expense view to $16M-$17M from $17M-$19MAugust 14, 2025 | msn.comTalphera Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | prnewswire.comA Preview Of Talphera's EarningsAugust 13, 2025 | benzinga.comTalphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025August 7, 2025 | prnewswire.comtalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLPH, LTRN, ACRV, and LVTX Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.34 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Lantern Pharma NASDAQ:LTRN$4.03 -0.05 (-1.23%) Closing price 04:00 PM EasternExtended Trading$4.15 +0.12 (+2.98%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.LAVA Therapeutics NASDAQ:LVTX$1.56 -0.01 (-0.64%) Closing price 04:00 PM EasternExtended Trading$1.56 0.00 (0.00%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Talphera NASDAQ:TLPH$0.54 0.00 (-0.18%) Closing price 04:00 PM EasternExtended Trading$0.53 -0.01 (-1.67%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Tests $412 Support as Options Traders Turn Bullish Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers Amazon Faces Rare Downgrade—Is the Rally at Risk? What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
